Literature DB >> 26822346

Use and Outcomes of Minimally Invasive Lobectomy for Stage I Non-Small Cell Lung Cancer in the National Cancer Data Base.

Chi-Fu Jeffrey Yang1, Zhifei Sun1, Paul J Speicher1, Shakir M Saud2, Brian C Gulack1, Matthew G Hartwig1, David H Harpole1, Mark W Onaitis1, Betty C Tong1, Thomas A D'Amico1, Mark F Berry3.   

Abstract

BACKGROUND: Previous studies have raised concerns that video-assisted thoracoscopic (VATS) lobectomy may compromise nodal evaluation. The advantages or limitations of robotic lobectomy have not been thoroughly evaluated.
METHODS: Perioperative outcomes and survival of patients who underwent open versus minimally-invasive surgery (MIS [VATS and robotic]) lobectomy and VATS versus robotic lobectomy for clinical T1-2, N0 non-small cell lung cancer from 2010 to 2012 in the National Cancer Data Base were evaluated using propensity score matching.
RESULTS: Of 30,040 lobectomies, 7,824 were VATS and 2,025 were robotic. After propensity score matching, when compared with the open approach (n = 9,390), MIS (n = 9,390) was found to have increased 30-day readmission rates (5% versus 4%, p < 0.01), shorter median hospital length of stay (5 versus 6 days, p < 0.01), and improved 2-year survival (87% versus 86%, p = 0.04). There were no significant differences in nodal upstaging and 30-day mortality between the two groups. After propensity score matching, when compared with the robotic group (n = 1,938), VATS (n = 1,938) was not significantly different from robotics with regard to nodal upstaging, 30-day mortality, and 2-year survival.
CONCLUSIONS: In this population-based analysis, MIS (VATS and robotic) lobectomy was used in the minority of patients for stage I non-small cell lung cancer. MIS lobectomy was associated with shorter length of hospital stay and was not associated with increased perioperative mortality, compromised nodal evaluation, or reduced short-term survival when compared with the open approach. These results suggest the need for broader implementation of MIS techniques.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26822346      PMCID: PMC4763985          DOI: 10.1016/j.athoracsur.2015.11.018

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  17 in total

Review 1.  Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer.

Authors:  Tristan D Yan; Deborah Black; Paul G Bannon; Brian C McCaughan
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

2.  Is video-assisted thoracoscopic lobectomy inferior to open lobectomy oncologically?

Authors:  Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2013-09       Impact factor: 4.330

3.  Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal.

Authors:  Bryan M Burt; Andrzej S Kosinski; Joseph B Shrager; Mark W Onaitis; Tracey Weigel
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-13       Impact factor: 5.209

4.  Transitioning from video-assisted thoracic surgical lobectomy to robotics for lung cancer: are there outcomes advantages?

Authors:  Benjamin E Lee; Robert J Korst; Elaine Kletsman; John R Rutledge
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-16       Impact factor: 5.209

5.  Comparing robot-assisted thoracic surgical lobectomy with conventional video-assisted thoracic surgical lobectomy and wedge resection: results from a multihospital database (Premier).

Authors:  Scott J Swanson; Daniel L Miller; Robert Joseph McKenna; John Howington; M Blair Marshall; Andrew C Yoo; Matthew Moore; Candace L Gunnarsson; Bryan F Meyers
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-08       Impact factor: 5.209

6.  Comparative effectiveness of robotic-assisted vs thoracoscopic lobectomy.

Authors:  Subroto Paul; Jessica Jalbert; Abby J Isaacs; Nasser K Altorki; O Wayne Isom; Art Sedrakyan
Journal:  Chest       Date:  2014-12       Impact factor: 9.410

7.  Open, video-assisted thoracic surgery, and robotic lobectomy: review of a national database.

Authors:  Michael Kent; Thomas Wang; Richard Whyte; Thomas Curran; Raja Flores; Sidhu Gangadharan
Journal:  Ann Thorac Surg       Date:  2013-10-01       Impact factor: 4.330

8.  Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections.

Authors:  Daniel J Boffa; Andrzej S Kosinski; Subroto Paul; John D Mitchell; Mark Onaitis
Journal:  Ann Thorac Surg       Date:  2012-06-27       Impact factor: 4.330

9.  A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer.

Authors:  Peter B Licht; Ole Dan Jørgensen; Lars Ladegaard; Erik Jakobsen
Journal:  Ann Thorac Surg       Date:  2013-05-16       Impact factor: 4.330

10.  The healthcare cost and utilization project: an overview.

Authors:  Claudia Steiner; Anne Elixhauser; Jenny Schnaier
Journal:  Eff Clin Pract       Date:  2002 May-Jun
View more
  37 in total

1.  Postoperative pain after lobectomy: robot-assisted, video-assisted and open thoracic surgery.

Authors:  Augustinus P T van der Ploeg; Ninos Ayez; George P Akkersdijk; Charles C van Rossem; Peter D de Rooij
Journal:  J Robot Surg       Date:  2019-03-29

2.  Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery.

Authors:  Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-13       Impact factor: 5.209

3.  Nodal upstaging evaluation in NSCLC patients treated by robotic lobectomy.

Authors:  Carmelina Zirafa; Vittorio Aprile; Sara Ricciardi; Gaetano Romano; Federico Davini; Ilenia Cavaliere; Greta Alì; Gabriella Fontanini; Franca Melfi
Journal:  Surg Endosc       Date:  2018-06-25       Impact factor: 4.584

4.  Minimally invasive lobectomy for early stage non-small cell lung cancer-it can be done without sacrificing oncologic outcomes.

Authors:  Mark F Berry
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

5.  Comparison of the Short- and Long-term Outcomes of Video-assisted Thoracoscopic Surgery versus Open Thoracotomy Bronchial Sleeve Lobectomy for Central Lung Cancer: A Retrospective Propensity Score Matched Cohort Study.

Authors:  Yanbo Yang; Jiandong Mei; Feng Lin; Qiang Pu; Lin Ma; Chengwu Liu; Yunke Zhu; Chenglin Guo; Liang Xia; Lunxu Liu
Journal:  Ann Surg Oncol       Date:  2020-07-08       Impact factor: 5.344

6.  Technical and operational modifications required for evolving robotic programs performing anatomic pulmonary resection.

Authors:  Benjamin Smood; Asem Ghanim; Benjamin Wei; Robert J Cerfolio
Journal:  J Robot Surg       Date:  2018-01-23

Review 7.  Troubleshooting in thoracoscopic anatomical lung resection for lung cancer.

Authors:  Atsushi Watanabe
Journal:  Surg Today       Date:  2020-09-17       Impact factor: 2.549

8.  Socioeconomic Factors Are Associated With Readmission After Lobectomy for Early Stage Lung Cancer.

Authors:  Rachel L Medbery; Theresa W Gillespie; Yuan Liu; Dana C Nickleach; Joseph Lipscomb; Manu S Sancheti; Allan Pickens; Seth D Force; Felix G Fernandez
Journal:  Ann Thorac Surg       Date:  2016-07-29       Impact factor: 4.330

9.  Outcomes after Video-assisted Thoracoscopic Lobectomy versus Open Lobectomy for Early-Stage Lung Cancer in Older Adults.

Authors:  Nicole Ezer; Minal Kale; Keith Sigel; Sameer Lakha; Grace Mhango; Emily Goodman; Daniel Nicastri; Scott Swanson; Alfred Neugut; Juan P Wisnivesky
Journal:  Ann Am Thorac Soc       Date:  2018-01

10.  Robotic esophagectomy: a better way or just another way?

Authors:  Jacob A Klapper; Matthew G Hartwig
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.